Hepatic

Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by AHR and RORγT, respectively, were higher in samples from patients with advanced fibrosis than in those with moderate fibrosis. In mouse models of hepatic inflammation, AHR or RORγT antagonist tool compounds decreased liver fibrosis compared with vehicle. Next steps could include testing other RORγT inhibitors in animal models of liver fibrosis.

Escalier Biosciences B.V. has the RORγT inhibitor ESR-114 in Phase I/II testing for mild to moderate psoriasis...